Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04710563 · ClinicalTrials.gov registry record

SCOPE-CLI: Shifting Care and Outcomes for Patients With Endangered Limbs

A clinical trial of Peripheral Arterial Disease, sponsored by Yale University.

Active
Registry status
458
Enrollment target
1
Study location

NCT04710563 is a study of Peripheral Arterial Disease that is active but no longer recruiting, run by Yale University. The registered enrollment target is 458 participants, below the 4,200-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04710563, a study of Peripheral Arterial Disease, is active but no longer recruiting, sponsored by Yale University.

ACTIVE NOT RECRUITING
Registry status
458 participants
Enrollment target
1
Study location

Study Summary

A research project capturing experiences of patients with critical limb threatening ischemia, with the ultimate goal of setting new standards for diagnosing, describing detailed patient-centered outcomes, and evaluating the variability in therapeutic approaches and their association with outcomes.

Study Locations (1)

Connecticut

  • Yale New Haven Health - New Haven

Trial Details

FieldValue
Enrollment Target 458 participants
Start Date 2021-08-11
Est. Completion 2028-09

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT04710563

The ClinicalTrials.gov registry entry for NCT04710563 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 458 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,200-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (89% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 0 interventions.

NCT04710563 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT04710563 about?

NCT04710563 is a clinical study titled "SCOPE-CLI: Shifting Care and Outcomes for Patients With Endangered Limbs". A research project capturing experiences of patients with critical limb threatening ischemia, with the ultimate goal of setting new standards for diagnosing, describing detailed patient-centered outcomes, and evaluating the variability in therapeutic approaches and their association with outcomes.

What is the current status of trial NCT04710563?

This trial is currently active not recruiting. The enrollment target is 458 participants. The study started on 2021-08-11. Estimated completion is 2028-09.

What conditions does trial NCT04710563 study?

This clinical trial studies the following conditions: Peripheral Arterial Disease.

Who is sponsoring clinical trial NCT04710563?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04710563 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Arterial Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.